SCHEMBL4148276

SCHEMBL4148276

Cc1ccncc1NC(=O)c1ccnc2[nH]c(-c3ccc(N4CCOCC4)cc3)nc12

nearest known ligand 0.52

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 8/20 0.52
GSK3A P49840 6/20 0.52
MAPT P10636 1/20 0.43
PARP1 P09874 2/20 0.42
DGAT1 O75907 1/20 0.42
JAK2 O60674 2/20 0.42
JAK3 P52333 1/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
PIM2 Q9P1W9 1/20 0.41
MAPK14 Q16539 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4153410 0.93 GSK3B (0.59) GSK3BGSK3AMAPTJAK2NPC1
SCHEMBL4149980 0.92 GSK3B (0.58) GSK3BGSK3AMAPTJAK2NPC1
SCHEMBL4165153 0.91 GSK3B (0.52) GSK3BGSK3APARP1JAK2PIM2
SCHEMBL4161803 0.85 GSK3B (0.47) GSK3BGSK3ARAB9AMAPK14
SCHEMBL4152895 0.85 GSK3B (0.60) GSK3BGSK3AMAPT
SCHEMBL4160369 0.84 GSK3B (0.46) GSK3BGSK3AMAPK14
SCHEMBL4152912 0.84 TP53 (0.53) GSK3BPARP1DGAT1NPC1RAB9A
SCHEMBL4161701 0.83 GSK3B (0.59) GSK3BGSK3AMAPTJAK2
SCHEMBL4147509 0.83 GSK3B (0.59) GSK3BGSK3AMAPT
SCHEMBL4152711 0.82 MAPK10 (0.54) MAPTPARP1DGAT1JAK2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US claimed
EP-1984370-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Crystalgenomics, Inc. (KR) 2008-10-29 EP claimed
WO-2007083978-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME CRYSTALGENOMICS, INC. (KR) 2007-07-26 WO claimed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
WO-2007083978-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME CRYSTALGENOMICS, INC. (KR) 2007-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same GSK3B, GSK3A, MAP3K3 GSK3B 1/4885GSK3A 2/4885MAPT 119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.